Pharma companies today have access to more data than ever before. AI, analytics, and dashboards are widely used across functions. Yet many critical decisions still falter—not due to a lack of information, but because data alone doesn’t drive action.
Our latest white paper, “From ‘What’ to ‘So What’: Making the Case for Decision Science Beyond Data Science”, highlights why decision science is a strategic necessity in pharma. It helps organizations determine their next steps, especially when the stakes are high and the future is uncertain.
Decision science brings structure and clarity to complex choices. It enables teams to define the right questions, evaluate real alternatives, and make aligned decisions under pressure. In an industry where every major decision is a bet on the future, this capability is essential.
The paper also explores how organizations can strengthen decision-making, not just through tools, but by embedding decision science into strategy, insights, and culture.
Read the full white paper to discover how decision science can complement your data efforts and improve decision quality across your organization.
Author
Jinsol Kim is an Associate Principal at EVERSANA. With a background in economics and years of consulting experience in healthcare and pharmaceuticals, he assists pharma companies in making strategic decisions in complex environments for…
In more than 20 years of consulting and leadership in APAC, Ravi’s expertise has focused on helping clients take big-bet investments in complex and uncertain environments at an asset and portfolio levels. Ravi regularly…
With over 30 years of consulting and executive leadership throughout Europe, North America, and Asia, Rob Arnold has developed creative solutions to some of the most challenging business situations in Life Sciences.. He’s responsible…